X
GO

Dr. Michele Carbone's Scientific Publications

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Published in Ca: A Cancer Journal for Clinicians, online version on July 9, 2019

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-associated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested.  The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapties are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.
0 Comments
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

published in Translational Lung Cancer Research, June 16, 2017

A review of the most promising biomarkers for early detection of malignant mesothelioma.
0 Comments
Mesothelioma: Recent Highlights

Mesothelioma: Recent Highlights

Annals of Translational Medicine 2017: Review Article

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. 
0 Comments
Proceedings of the National Academy of Sciences of the United States of America

Proceedings of the National Academy of Sciences of the United States of America

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma

We found that gene mutations/deletions are frequent in mesothelioma and occur through a variety of DNA alterations. We identified genes implicated in malignant mesothelioma: SETD2, SMARCC1, PBRM1.
0 Comments
Malignant Mesothelioma: Time to Translate?

Malignant Mesothelioma: Time to Translate?

Opinion: Lessons from the Clinic

Malignant Mesothelioma is a rare and poorly understood cancer with limited therapeutic approaches.

0 Comments
RSS
12